Gemcitabine + Cisplatin + Sunitinib Malate
Phase 2Terminated 0 watching 0 views this week⚡ Active
51
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Transitional Cell Carcinoma of the Bladder
Conditions
Transitional Cell Carcinoma of the Bladder
Trial Timeline
Mar 1, 2009 → Apr 1, 2011
NCT ID
NCT00859339About Gemcitabine + Cisplatin + Sunitinib Malate
Gemcitabine + Cisplatin + Sunitinib Malate is a phase 2 stage product being developed by Pfizer for Transitional Cell Carcinoma of the Bladder. The current trial status is terminated. This product is registered under clinical trial identifier NCT00859339. Target conditions include Transitional Cell Carcinoma of the Bladder.
Hype Score Breakdown
Clinical
17
Activity
12
Company
9
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00859339 | Phase 2 | Terminated |
Competing Products
20 competing products in Transitional Cell Carcinoma of the Bladder
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Enfortumab vedotin | Astellas Pharma | Phase 2 | 52 |
| enfortumab vedotin (EV) + pembrolizumab + cisplatin + carboplatin + gemcitabine | Astellas Pharma | Phase 1/2 | 41 |
| Pemetrexed + Gemcitabine + Platinol | Eli Lilly | Phase 1/2 | 41 |
| Vepugratinib + EV + Pembrolizumab | Eli Lilly | Phase 3 | 77 |
| durvalumab and tremelimumab | AstraZeneca | Phase 2 | 52 |
| Docetaxel + vandetanib + Placebo | AstraZeneca | Phase 2 | 52 |
| MK-3475 and BCG | Merck | Phase 2 | 52 |
| Pembrolizumab | Merck | Phase 2 | 52 |
| Everolimus + Everolimus + Paclitaxel | Novartis | Phase 2 | 52 |
| Buparlisib | Novartis | Phase 2 | 52 |
| BEZ235 | Novartis | Phase 2 | 52 |
| Atezolizumab | Roche | Phase 3 | 77 |
| Nivolumab/Ipilimumab | Bristol Myers Squibb | Phase 2 | 51 |
| vinflunine and best supportive care | Bristol Myers Squibb | Phase 3 | 76 |
| vinflunine | Bristol Myers Squibb | Phase 2 | 51 |
| Dasatinib | Bristol Myers Squibb | Pre-clinical | 22 |
| Docetaxel + Oxaliplatin | Sanofi | Phase 2 | 51 |
| Cabazitaxel | Sanofi | Phase 2/3 | 64 |
| Rogaratinib (BAY1163877) + Chemotherapy | Bayer | Phase 2/3 | 62 |
| CG0070 Adenovirus Vector | CG Oncology | Phase 2/3 | 62 |